Headline results for the first quarter: Revenue: JPY 375 billion ($2.6 billion), down 1.8% Profit: JPY 33.1 billion ($232 million), up 33.5%Note: All changes are versus the prior-year period unless otherwise statedWhat the company said:Astellas noted that while sales of key products including Xtandi, Padcev and Xospata showed "steady growth" during the first quarter, revenue from Lexiscan in the US plunged nearly 85% to JPY 29 billion due to generic competition.Other results: Xtandi: JPY 174.1 billion, up 7.2% Betanis, Myrbetriq and Betmiga: JPY 49.2 billion, up 2.7% Prograf: JPY 49.1 billion, down 5.3% Padcev: JPY 15.2 billion, up 44.2% Xospata: JPY 13 billion, up 24.2% Vesicare: JPY 3.7 billion, down 8.4% Evrenzo: JPY 1 billion, up 31%Looking ahead:Astellas reaffirmed that it expects revenue for fiscal year 2023 of JPY 1.52 trillion ($10.7 billion), broadly in line with the prior 12-month period, with sales of Xtandi reaching nearly JPY 670 billion ($4.7 billion billion). Meanwhile, core profit is seen growing 1.5% to JPY 228 billion ($1.6 billion).Pipeline updates:The company disclosed that it discontinued Phase I development of ASP0598 for chronic tympanic membrane perforation.($1 = JPY 142.715)
